What is Bright Biotech?
Bright Biotech operates as a Contract Manufacturing and Development Organization (CMDO) with a specialization in plant-based expression and production. The company focuses on delivering high-quality and affordable recombinant proteins tailored for a diverse range of applications, including research and development, therapeutics, cosmeceuticals, agri-food, and industrial uses. Their expertise in leveraging plant systems for protein production positions them as a key player in the biomanufacturing landscape, offering innovative solutions for various industries.
How much funding has Bright Biotech raised?
Bright Biotech has raised a total of $3.2M across 1 funding round:
Angel/Seed
$3.2M
Angel/Seed (2022): $3.2M with participation from FoodLabs, CPT Capital, and Big Idea Ventures
Key Investors in Bright Biotech
FoodLabs
FoodLabs is a Berlin-based firm dedicated to backing innovative companies focused on improving planetary and human health through food technology. They support entrepreneurs in creating iconic products like animal-free cheese, guilt-free meat, and sustainable soft drinks.
CPT Capital
CPT Capital is an investment firm focused on the future of food and materials, specifically in the alternative protein sector. They partner with visionary founders and companies that utilize cutting-edge technologies to replace animals in the supply chain.
Big Idea Ventures
Big Idea Ventures is a venture capital fund and startup accelerator focused on addressing global food challenges by investing in innovative companies in the food tech sector. Their Global Food Innovation Fund and accelerator program support startups developing alternative proteins, ingredients, and sustainable food solutions.
What's next for Bright Biotech?
The recent major enterprise-level funding indicates a strategic push for Bright Biotech to scale its operations and potentially expand its service offerings or technological capabilities. This capital infusion is likely to accelerate the company's growth trajectory, enabling further development of its plant-based expression platforms and strengthening its market position in the recombinant protein production sector. Future endeavors may include forging new partnerships, enhancing production capacity, and exploring novel applications for its proprietary technology.
See full Bright Biotech company page
